268 related articles for article (PubMed ID: 32965680)
21. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
22. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.
Scott EC; Hari P; Sharma M; Le-Rademacher J; Huang J; Vogl D; Abidi M; Beitinjaneh A; Fung H; Ganguly S; Hildebrandt G; Holmberg L; Kalaycio M; Kumar S; Kyle R; Lazarus H; Lee C; Maziarz RT; Meehan K; Mikhael J; Nishihori T; Ramanathan M; Usmani S; Tay J; Vesole D; Wirk B; Yared J; Savani BN; Gasparetto C; Krishnan A; Mark T; Nieto Y; D'Souza A
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1893-1899. PubMed ID: 27496215
[TBL] [Abstract][Full Text] [Related]
23. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.
Beksac M; Eikema DJ; Koster L; Hulin C; Poiré X; Hamladji RM; Gromek T; Bazarbachi A; Ozkurt ZN; Pabst T; Ben Othman T; Finke J; Pirogova O; Wu D; Hayat A; Hilgendorf I; Tholouli E; de Wreede LC; Schönland S; Garderet L; Drozd-Sokolowska J; Raj K; Hayden PJ; Yakoub-Agha I; McLornan DP
Bone Marrow Transplant; 2024 Apr; 59(4):526-533. PubMed ID: 38297040
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.
Parrondo RD; Reljic T; Iqbal M; Ayala E; Tun HW; Kharfan-Dabaja MA; Kumar A; Murthy HS
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e694-e711. PubMed ID: 32616401
[TBL] [Abstract][Full Text] [Related]
25. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma.
Dhakal B; D'Souza A; Callander N; Chhabra S; Fraser R; Davila O; Anderson K; Assal A; Badawy SM; Berdeja J; Cerny J; Comenzo R; Chakraborty R; Peter Gale R; Kamble R; Kharfan-Dabaja MA; Krem M; Ganguly S; Janakiram M; Kansagra A; Munker R; Murthy H; Patel S; Kumar S; Shah N; Qazilbash M; Hari P
Br J Haematol; 2020 Nov; 191(3):442-452. PubMed ID: 33094839
[TBL] [Abstract][Full Text] [Related]
26. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care.
Bostankolu Değirmenci B; Yegin ZA; Akdemir ÜÖ; Dede A; Gündem GG; Özkurt ZN; Atay LÖ; Yağcı M
Ann Hematol; 2024 Jan; 103(1):269-283. PubMed ID: 37880484
[TBL] [Abstract][Full Text] [Related]
27. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
28. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
Kumar L; Sahoo RK; Kumar S; Baa AK; Tansir G; Pathak N; Malik PS; Sharma OD; Mathew A; Jha A; Gupta R; Sharma A; Biswas A; Kumar R; Thulkar S; Malik S; Dutt A;
Leuk Lymphoma; 2023 Feb; 64(2):378-387. PubMed ID: 36416679
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
[TBL] [Abstract][Full Text] [Related]
30. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
31. Autologous stem cell transplantation for multiple myeloma: Long-term results.
Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
[TBL] [Abstract][Full Text] [Related]
32. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.
Vogl DT; Wang T; Pérez WS; Stadtmauer EA; Heitjan DF; Lazarus HM; Kyle RA; Kamble R; Weisdorf D; Roy V; Gibson J; Ballen K; Holmberg L; Bashey A; McCarthy PL; Freytes C; Maharaj D; Maiolino A; Vesole D; Hari P
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1765-74. PubMed ID: 21624486
[TBL] [Abstract][Full Text] [Related]
33. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
34. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
Cordas Dos Santos DM; Saliba RM; Patel R; Bashir Q; Saini N; Hosing C; Kebriaei P; Khouri IF; Nieto Y; Popat U; Ahmed H; Lee HC; Manasanch EE; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1077-1083. PubMed ID: 31786242
[TBL] [Abstract][Full Text] [Related]
35. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
Pasvolsky O; Yeshurun M; Fraser R; Estrada-Merly N; Rozovski U; Shargian-Alon L; Assal A; Banerjee R; Bumma N; Gale RP; Hagen P; Holmberg L; Hossain NM; Lazarus HM; Lee C; Mian H; Miller KC; Nathan S; Nagler A; Nishihori T; Parrondo RD; Patel S; Schroeder MA; Usmani SZ; Wang T; Wirk B; Kumar S; Shah N; Qazilbash MH; D'Souza A
Bone Marrow Transplant; 2022 Jan; 57(1):31-37. PubMed ID: 34608275
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
[TBL] [Abstract][Full Text] [Related]
39. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
40. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]